文献速递青光眼

PreserFlo MicroShunt治疗青光眼的1年手术结局:一项多中心分析

One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis.
PubMed 文献 · Br J Ophthalmol · 2022-04-01

该多中心队列研究纳入英国三家三级中心2019年5月至2020年9月连续接受PreserFlo MicroShunt联合丝裂霉素C(MMC)0.4 mg/mL治疗的患者,1年完全成功率为51.9%、条件成功率为16.4%、失败率为31.7%,眼压和抗青光眼药物均显著降低,并发症发生率较低。

要点

  • 1年完全成功54眼(51.9%),条件成功17眼(16.4%),失败33眼(31.7%)。
  • 眼压从术前23.4±0.8 mmHg降至12个月14.7±0.6 mmHg(p<0.0001)。
  • 抗青光眼药物从术前3.4±0.1种降至12个月0.7±0.1种(p<0.0001)。

核心结论

  • PreserFlo MicroShunt联合MMC 0.4 mg/mL的1年总体成功率为68.3%,眼压和药物显著降低且不良事件发生率低。

研究设计与样本

  • 多中心队列研究,纳入英国三家三级中心2019年5月至2020年9月连续接受PreserFlo MicroShunt联合MMC 0.4 mg/mL治疗的患者,104眼完成1年随访。

主要发现

  • 1年完全成功54眼(51.9%),条件成功17眼(16.4%),失败33眼(31.7%)。
  • 眼压从术前23.4±0.8 mmHg(N=104)降至12个月14.7±0.6 mmHg(N=104)(p<0.0001)。
  • 抗青光眼药物从术前3.4±0.1种(N=104)降至12个月0.7±0.1种(N=104)(p<0.0001)。
  • 多变量分析显示较高平均偏差与失败相关(HR 1.055,95%CI 1.0075至1.11,p=0.0227)。
  • 并发症包括低眼压20眼(19.2%)、脉络膜脱离11眼(10.6%)、前房积血6眼(5.8%)和滤过泡渗漏6眼(5.8%)。

关键数值与推荐

  • 完全成功定义为眼压≤21 mmHg且较基线降低≥20%,无二次手术或视力丧失等失败事件。
  • 失败定义为眼压>21 mmHg或降低<20%、连续两次随访眼压≤5 mmHg伴视力下降、再次手术或光感丧失。
  • 针拨和5-氟尿嘧啶注射分别 performed in 13眼(12.5%)和35眼(33.7%),12眼(11.5%)需修正手术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To evaluate the efficacy and safety of the PreserFlo MicroShunt glaucoma device in a multicentre cohort study. METHODS: All consecutive patients who received the microshunt with mitomycin-C (MMC) 0.4 mg/mL from May 2019 to September 2020 in three UK tertiary centres. Primary outcome at 1 year was a complete success, with failure defined as intraocular pressure (IOP) >21 mmHg or <20% reduction, IOP≤5 mmHg with any decreased vision on two consecutive visits, reoperation or loss of light perception vision. Secondary outcomes were IOP, best-corrected visual acuity, medications, complications, interventions and reoperations. We also performed subgroup analyses for severe glaucoma and assessed risk factors for failure. RESULTS: 104 eyes had 1-year follow-up. Complete and qualified success at 1 year were achieved in 51.9% (N=54) and 16.4% (N=17), respectively, and failure occurred in 31.7% (N=33). There was a significant reduction in IOP (mmHg) from preoperatively (23.4±0.8, N=104) to 12 months (14.7±0.6, N=104) (p<0.0001). Antiglaucoma medications also decreased from preoperatively (3.4±0.1, N=104) to 12 months (0.7±0.1, N=104) (p<0.0001). Multivariate analyses showed an association between higher mean deviation and failure (HR 1.055, 95% CI 1.0075 to 1.11, p=0.0227). Complications were hypotony (19.2%; N=20), choroidal detachments (10.6%; N=11), hyphaema (5.8%; N=6) and bleb leak (5.8%; N=6). Needling and 5-fluorouracil injections were performed in 12.5% (N=13) and 33.7% (N=35), respectively, and 11.5% (N=12) required revision surgery. CONCLUSION: The PreserFlo MicroShunt with MMC 0.4 mg/mL showed an overall success rate of 68.3% at 1 year, and led to significant IOP and medication reduction with a low rate of adverse effects.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Tanner A, Haddad F, Fajardo-Sanchez J, et al. One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis. Br J Ophthalmol. 2022. PMID: 35365491. doi:10.1136/bjophthalmol-2021-320631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。